RYTM250117C20000
- 0.00
- 0.000.00%
Rhythm Pharmaceuticals Newsroom
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
Strategic Advancements and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals
Rhythm Gets FDA Approval for Imcivree for Toddlers
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases
Express News | Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients as Young as 2 Years Old
Oppenheimer Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $76
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Initiated at Outperform by Oppenheimer
Rhythm Pharmaceuticals Price Target Announced at $76.00/Share by Oppenheimer
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $66
Rhythm Pharmaceuticals Price Target Raised to $66.00/Share From $59.00 by Goldman Sachs
Rhythm Pharmaceuticals Is Maintained at Buy by Goldman Sachs
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $75
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Ahead of October JOLTS Report
Express News | Rhythm Pharmaceuticals Inc - Imcivree Expected to Be Available by Year-End Through Medicines for Children Program
Express News | Rhythm Pharmaceuticals Announces ▼ Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients With Bardet Biedl Syndrome or Pomc, Pcsk1, or Lepr Deficiency to Includ